VU0152100 is a selective negative allosteric modulator (antagonist) of the mGluR5 (metabotropic glutamate receptor 5), primarily used in research settings to study the role of this receptor in the brain. It is particularly involved in neurological and psychiatric disorders, helping scientists understand the mechanisms underlying conditions like anxiety, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and post-traumatic stress disorder (PTSD). By modulating mGluR5 activity, it provides insights into neural pathways related to learning, memory, and behavior, contributing to potential therapeutic targets for developing new treatments in neuroscience and pharmacology. It is utilized in preclinical studies to explore its effects on behavior and neural pathways.